Articles tagged with Growth Factors
Researchers found that functional electrical stimulation promotes endogenous neural precursor cell proliferation and improves motor function in acute cerebral infarction rats. The treatment also enhances expression of basic fibroblast growth factor and epidermal growth factor.
A new technology uses microparticles of heparin to bind and deliver the potent protein BMP-2, reducing unwanted bone formation and increasing efficiency. The study found that the microparticles maintained high bioactivity and released growth factor slowly over time.
Researchers at EPFL have developed bioengineered growth factors that significantly enhance wound healing, bone repair, and new blood vessel formation. The engineered growth factors display improved binding affinity to extracellular matrix proteins, leading to faster tissue closure and granulation tissue production.
Duke researchers have successfully used gene therapy to induce stem cells to produce growth factor proteins, overcoming the challenge of delivering these proteins after implantation. The technique allows for long-term delivery and could be applied to various orthopedic tissues, presenting a significant step toward commercialization.
Two proteins, phospholipase Cγ1 and growth factor receptor bound protein 2 (Grb2), compete for binding to FGFR2 with distinct effects on cancer cell behavior. High levels of Plcγ1 lead to increased metastasis, while high Grb2 levels inhibit this process.
Research reveals that gut villification is caused by mechanical compression of the epithelium sheet, rather than active mechanisms involving growth factors. This process involves the spontaneous buckling of the epithelium into longitudinal folds and zigzag patterns, ultimately forming villi.
Researchers found that Noggin accelerates and increases the differentiation of neural precursors, outperforming basic fibroblast growth factor (bFGF). Noggin's greater effect was observed in inducing neural precursor differentiation from human embryonic stem cells.
Researchers engineered 'helper cells' to provide growth factors to transplanted stem cells, increasing their endurance and survival rate. The study aims to overcome a major barrier to successful stem cell therapy.
Recent studies suggest that HB-EGF can protect the intestines from various types of injury, including those caused by radiation therapy. The protein's ability to decrease harmful substance production and promote cell growth makes it a promising therapeutic option for treating necrotizing enterocolitis in newborns.
Researchers found that environmental enrichment, including running and exposure to novel objects, improved neurobehavioral function in mice after transplanting adipose-derived stem cells. Exercise-induced fibroblast growth factor 2 enhanced brain repair by promoting angiogenesis, neurogenesis, and astrocytic activation.
Researchers have developed a new bio-mimicking therapeutic that can stabilize bFGF, allowing for its potential use in treating skin wounds and accelerating the healing process. The stable conjugate has been shown to function like normal bFGF to trigger the same signaling pathways involved in wound healing.
Researchers have developed a new and effective way to regrow blood vessels, potentially bypassing surgery and repairing damaged vessels through injection of a lipid-incased substance. This method has shown promise in treating chronic myocardial ischemia disease, affecting up to 27 million patients in the US.
Researchers at Case Western Reserve University developed a method to engineer cartilage replacements using mesenchymal stem cells and tiny beads filled with growth factor. The new approach showed promising results in creating thicker, stiffer cartilage than previous methods.
Dr. Gail Besner continues her research on HB-EGF for treating neonatal necrotizing enterocolitis (NEC), a leading cause of surgical death in premature infants. Recent data suggest that HB-EGF may improve intestinal function after NEC treatment.
Researchers block PlGF to increase life expectancy in CML mice, even those resistant to imatinib. Chronic myeloid leukemia's uncontrolled white blood cell production is disrupted by a disruption in maturing process.
Researchers discovered that cancerous cells quickly divide after receiving a growth factor signal because their p53 gene is defective. Healthy cells, on the other hand, wait eight continuous hours before dividing to ensure they receive necessary signals.
Heparan sulfate on human cells modifies growth factor proteins' connection to cell surfaces. The structure and interaction of heparan sulfate chains with growth factors determine normal cell growth.
Researchers at Rice University aim to develop an injectable mix of polymers and adult stem cells to regenerate articular cartilage in injured knees and joints. The team hopes to find the optimal formulation of MSCs and growth factors for regenerating new cartilage.
BioSET Inc. has been issued a patent for improved second-generation technology to design synthetic peptides that communicate growth signals to cells, fostering efficient healing. The technology has applications in numerous tissue repair cases, including orthopedic markets and sports medicine injuries.
A new treatment to restore brain cells damaged by stroke has passed the safety stage of a clinical trial led by UC Irvine neurologist Dr. Steven C. Cramer. Patients showed no ill effects after receiving sequential growth factors that encourage neuron creation in stroke-damaged areas of the brain.
Researchers design a bioactive nanomaterial that activates bone marrow stem cells to produce natural cartilage. The treatment shows promise in repairing damaged joints with better results than conventional microfracture procedures.
Researchers from Caltech found that contact inhibition is a tunable system influenced by growth factors like EGF. They discovered a threshold of sensitivity to EGF that can be manipulated to control cell division and tissue growth.
Researchers have found that cancer cells use glucose to avoid programmed cell death and maintain survival through the protein Akt. By exploiting this mechanism, cancer cells can bypass normal safeguards and continue to grow even without growth factors.
Researchers have discovered a new potential cancer therapy that targets angiogenesis, the formation of blood vessels that feed tumor cells. Anti-PLGF inhibits the growth of VEGF(R)-resistant tumors without affecting healthy vessels, offering a promising alternative to existing treatments.
Researchers have found that boosting HLA-G production can make dendritic cells less responsive to transplanted tissue, reducing rejection. This natural immunosuppression approach has the potential to prolong acceptance of skin grafts and other transplanted tissues.
Human embryonic stem cells (hESCs) can be grown using a simple mix called hESC cocktail, or HESCO, containing purified human factors. The recipe maintains normal cell chromosome profiles and supports differentiation into all three basic cell lineages.
Transforming growth factor-alpha (TGF-α) has emerged as a paradigmatic growth factor, defining cell- and context-specific actions attributed to many growth factors. Dr. Anita Roberts will discuss TGF-α's role in wound healing, autoimmune disease, fibrosis, and cancer, and several therapeutic strategies based on the growth factor.
Researchers developed a synthetic peptide, B2A2, that unlocks synergy with BMP-2, increasing its effectiveness in bone formation. The peptide is part of a series of growth factors being developed by Brookhaven/BioSET collaboration.
Fibroblast Growth Factors, such as Fgf8, play crucial roles in cellular decisions during development. Endocytosis regulates the spreading and effective signaling range of Fgf8 protein by controlling its internalization and degradation within cells. This process allows target cells to actively influence signal availability.
Researchers found that c-Myc is essential for tumor development by regulating blood vessel growth. The study suggests disrupting c-Myc may be a successful anti-angiogenic tool in cancer therapy, targeting tumors' vascular networks to slow growth.
Syndecan-4 is essential for wound repair, as its knockout leads to marked defects in angiogenesis and tissue healing. In contrast, fibroblasts from syndecan-4-deficient mice display normal focal adhesion assembly and response to FGF-2.
Researchers have produced two blood factors that treat most patients with blood clotting disorders. The production of human blood proteins in plants eliminates disease transmission risk, making lifesaving treatments more accessible. This technology is expected to be 10 times cheaper than current methods and provides a stable production...